Coverage Guide · Updated April 28, 2026
Does Kaiser Permanente Cover Wegovy? (2026 Coverage Guide)
Sometimes covered, varies by plan for Kaiser Permanente members in 2026. Wegovy is FDA-approved for chronic weight management. Coverage depends on your specific plan, employer benefits, and prior authorization rules.
1. Kaiser Permanente coverage status for Wegovy
| Detail | Status |
|---|---|
| Plan type | Commercial |
| Coverage status | Sometimes covered, varies by plan |
| FDA indication | chronic weight management |
| List price | $1349/mo (cash-pay retail) |
| Manufacturer direct | NovoCare cash-pay, about $499/mo |
| Appeal success rate | ~28% when denied |
2. Kaiser Permanente's coverage rules
Kaiser is more restrictive than other commercial plans on GLP-1 coverage for weight loss. Their integrated medical-pharmacy model means decisions are made at the regional formulary committee. Some Kaiser regions cover only the diabetes indication.
3. Prior authorization requirements
Most Kaiser Permanente plans require:
- BMI 30+ (or 27+ with at least one comorbidity such as type 2 diabetes, hypertension, sleep apnea, or non-alcoholic fatty liver disease)
- Documented prior weight-loss attempts (often 6 months of supervised diet and exercise)
- No contraindications (medullary thyroid carcinoma history, MEN-2)
- Some plans require step therapy through a cheaper drug first (often phentermine or metformin)
Prior auth approval typically takes 3 to 14 days. Some prescribers offer PA submission as part of the visit, which speeds the process.
4. If denied: how to appeal
Kaiser Permanente appeals succeed about 28% of the time when prepared properly. Steps:
- Request the formal denial letter (your right under federal law). It will list the specific reason for denial.
- Have your prescriber write a letter of medical necessity. Should document BMI, comorbidities, prior weight-loss attempts, contraindications to cheaper alternatives, and any cardiovascular risk factors.
- Submit the appeal within the deadline (usually 30 to 180 days depending on plan).
- If denied at first appeal, escalate to second-level review or external review.
5. If uncovered: cheapest alternatives for Kaiser Permanente members
- NovoCare cash-pay: about $499/mo. Direct from the manufacturer, no insurance required.
- Manufacturer savings card: as low as $25/mo for eligible commercial-insurance patients. May apply to your plan.
- Compounded semaglutide: $80 to $349/mo for compounded semaglutide, $132 to $600/mo for compounded tirzepatide. Cash-pay only.
- Switch to the diabetes-indicated version (Mounjaro or Ozempic) if you have type 2 diabetes, which has higher coverage rates.
FAQ
Does Kaiser Permanente cover Wegovy in 2026?
Sometimes covered, varies by plan for Kaiser Permanente members. Wegovy is FDA-approved for chronic weight management. Coverage depends on your specific plan, employer benefits (for commercial plans), and prior authorization requirements. Kaiser is more restrictive than other commercial plans on GLP-1 coverage for weight loss. Their integrated medical-pharmacy model means decisions are made at the regional formulary committee. Some Kaiser regions cover only the diabetes indication.
What is the prior authorization process for Wegovy on Kaiser Permanente?
Most Kaiser Permanente plans require: BMI 30+ (or 27+ with comorbidity), documented prior weight-loss attempts (often 6 months), no contraindications, and sometimes step therapy through cheaper drugs first. Approval usually takes 3 to 14 days.
If Kaiser Permanente denies Wegovy, can I appeal?
Yes. Kaiser Permanente appeal success rate for GLP-1 denials is approximately 28%. Strongest appeals document BMI, comorbidities (diabetes, hypertension, sleep apnea, NAFLD), prior weight-loss attempts, and any contraindications to alternative drugs.
If insurance won't cover Wegovy, what is the cheapest alternative?
Three options. First, NovoCare cash-pay from the manufacturer at about $499/mo. Second, the manufacturer savings card if you have commercial insurance ($25/mo for eligible patients). Third, compounded semaglutide from a licensed compounding pharmacy ($80 to $349/mo for compounded semaglutide, $132 to $600/mo for compounded tirzepatide).